Alzheimer's disease research

Search documents
Davos Alzheimer’s Collaborative Selects PacBio as Technology Partner for Global Project to Advance Alzheimer’s Disease Research in North Africa
Globenewswire· 2025-04-22 13:05
Core Viewpoint - The Davos Alzheimer's Collaborative (DAC) is launching the North African Dementia Registry (NADR) project in collaboration with PacBio, The American University in Cairo (AUC), and UCL to enhance understanding of Alzheimer's disease and dementia in diverse populations, particularly in North Africa [1][2][3] Group 1: Project Overview - The NADR is the first dementia-focused registry in North Africa, aiming to collect biosamples, conduct cognitive assessments, and perform digital phenotyping [2] - The initiative will create a comprehensive multi-omics dataset to explore genetic and environmental factors related to Alzheimer's disease [2][3] - Data generated will be accessible via the Alzheimer's Disease Data Initiative (ADDI) platform, promoting global research collaboration [3] Group 2: Technological Partnership - PacBio will provide its advanced long-read sequencing technology to generate high-quality genomic data essential for understanding the genetic landscape of Alzheimer's disease [2][3] - The collaboration aims to identify new diagnostic tools and therapeutic solutions for Alzheimer's disease [3] Group 3: Importance of Diversity in Research - The project addresses the underrepresentation of North African populations in dementia research, which is crucial given the region's genetic diversity [2][3] - Insights gained from this research are expected to inform locally relevant prevention and intervention strategies [3] Group 4: Broader Implications - DAC aims to extend global research efforts beyond traditional Western populations to include diverse populations in the Global South, where most Alzheimer's patients reside [4] - The initiative aligns with DAC's goal to implement health system solutions that are globally applicable and to promote brain health throughout the lifespan [4][5]
Davos Alzheimer's Collaborative Selects PacBio as Technology Partner for Global Project to Advance Alzheimer's Disease Research in North Africa
Newsfilter· 2025-04-22 13:04
Core Insights - The Davos Alzheimer's Collaborative (DAC) has partnered with PacBio to support the North African Dementia Registry (NADR) project, aiming to enhance understanding of Alzheimer's disease in North African populations [1][2][3] - This initiative is the first dementia-focused registry in North Africa, addressing the underrepresentation of these populations in dementia research [2][3] - The collaboration will utilize PacBio's long-read sequencing technology to create a comprehensive multi-omics dataset, facilitating research into genetic and environmental factors related to Alzheimer's disease [2][3] Company Insights - PacBio is recognized for its advanced sequencing solutions, which are crucial for generating high-quality genomic data necessary for understanding the complex genetic landscape of Alzheimer's disease [3][12] - The partnership aligns with PacBio's commitment to enabling genomic discoveries that improve human health globally [3][12] - The data generated from this collaboration will be accessible through the Alzheimer's Disease Data Initiative (ADDI) platform, promoting further research and innovation in Alzheimer's disease [3][4] Industry Insights - The DAC initiative aims to extend global research efforts beyond traditional Western populations to include diverse populations in the Global South, where a significant number of Alzheimer's cases exist [4] - By 2050, it is projected that over 150 million families and half a billion people will be affected by dementia, highlighting the urgent need for effective research and intervention strategies [4] - The NADR project will enable the collection of biosamples, cognitive assessments, and digital phenotyping, which are essential for developing locally relevant prevention and intervention strategies [2][3]
InMed Pharmaceuticals (INM) Update / Briefing Transcript
2024-11-12 20:00
InMed Pharmaceuticals (INM) Update / Briefing November 12, 2024 02:00 PM ET Speaker0 Hello, everyone. Thank you for attending today's Fierce Biotech webinar, Alzheimer's Outlook, The Next Step. I understand we have a great number of attendees on today's webinar, and I want to thank InMed Pharmaceuticals for sponsoring this presentation. My name is Phyllis Fearle, and I will be moderating today's conversation. But before we get started, here's a few quick housekeeping notes. You can access closed captions fr ...